文献速递儿童青少年精神

鼻内催产素对孤独症谱系障碍核心社交症状随机临床试验

Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial.
PubMed 文献 · Mol Psychiatry · 2018-06-29

日本多中心随机双盲安慰剂对照试验纳入106例18-48岁孤独症谱系障碍个体,比较6周鼻内催产素48IU/日与安慰剂。主要终点ADOS互惠性两组均改善但组间无差异;催产素改善重复行为及社会相关区域注视时长,不良事件无显著差异。

要点

  • 鼻内催产素48IU/日6周未显著改善成人高功能孤独症核心社交症状(ADOS互惠性)。
  • 催产素组重复行为及社会相关区域注视时长较安慰剂组显著改善。
  • 不良事件两组无显著差异,1例催产素组出现暂时性男性乳房发育。

核心结论

  • 当前剂量与疗程的鼻内催产素单药治疗不能推荐用于成人男性高功能孤独症核心社交症状。
  • 催产素可能对孤独症重复行为有治疗潜力。

研究设计与样本

  • 随机、平行组、多中心、安慰剂对照、双盲试验,在日本开展。

主要发现

  • 主要终点ADOS互惠性:催产素组从8.5降至7.7(P<.001),安慰剂组从8.3降至7.2(P<.001),组间无差异(效应量-0.08;95%CI -0.46至0.31;P=.69)。
  • 血浆催产素仅催产素组从基线至终点升高,与安慰剂组比较有差异(效应量-1.12;95%CI -1.53至-0.70;P<.0001)。
  • 次要终点ADOS重复行为:催产素组从2.0降至1.5(P<.0001),安慰剂组从2.0降至1.8(P=.43),组间效应量0.44(95%CI 0.05至0.83;P=.026)。
  • 次要终点社会相关区域注视时长:催产素组从41.2增至52.3(P=.03),安慰剂组从45.7降至40.4(P=.25),组间效应量0.55(95%CI 0.10至1.0;P=.018)。
  • 其他次要终点无显著效应;不良事件发生率两组无显著差异,催产素组1例出现给药期间暂时性男性乳房发育。

临床怎么用

  • 不支持对成人男性高功能孤独症核心社交症状使用当前剂量和疗程的鼻内催产素单药治疗。
  • 催产素对重复行为及社会注视的改善提示需进一步研究不同剂量、疗程或联合干预。

局限性

  • 研究仅纳入成人男性高功能孤独症个体,结论不能外推至女性、儿童或低功能孤独症人群。
  • 干预疗程为6周,长期效果未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although small-scale studies have described the effects of oxytocin on social deficits in autism spectrum disorder (ASD), no large-scale study has been conducted. In this randomized, parallel-group, multicenter, placebo-controlled, double-blind trial in Japan, 106 ASD individuals (18-48 y.o.) were enrolled between Jan 2015 and March 2016. Participants were randomly assigned to a 6-week intranasal oxytocin (48IU/day, n = 53) or placebo (n = 53) group. One-hundred-three participants were analyzed. Since oxytocin reduced the primary endpoint, Autism Diagnostic Observation Schedule (ADOS) reciprocity, (from 8.5 to 7.7; P < .001) but placebo also reduced the score (8.3 to 7.2; P < .001), no between-group difference was found (effect size -0.08; 95% CI, -0.46 to 0.31; P = .69); however, plasma oxytocin was only elevated from baseline to endpoint in the oxytocin-group compared with the placebo-group (effect size -1.12; -1.53 to -0.70; P < .0001). Among the secondary endpoints, oxytocin reduced ADOS repetitive behavior (2.0 to 1.5; P < .0001) compared with placebo (2.0 to 1.8; P = .43) (effect size 0.44; 0.05 to 0.83; P = .026). In addition, the duration of gaze fixation on socially relevant regions, another secondary endpoint, was increased by oxytocin (41.2 to 52.3; P = .03) compared with placebo (45.7 to 40.4; P = .25) (effect size 0.55; 0.10 to 1.0; P = .018). No significant effects were observed for the other secondary endpoints. No significant difference in the prevalence of adverse events was observed between groups, although one participant experienced temporary gynecomastia during oxytocin administration. Based on the present findings, we cannot recommend continuous intranasal oxytocin treatment alone at the current dose and duration for treatment of the core social symptoms of high-functioning ASD in adult men, although this large-scale trial suggests oxytocin's possibility to treat ASD repetitive behavior.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Yamasue H, Okada T, Munesue T, et al. Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial. Mol Psychiatry. 2018. PMID: 29955161. doi:10.1038/s41380-018-0097-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。